Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of subcutaneous amlitelimab in adults with moderate to severe atopic dermatitis
2021-002344-73Phase 2Active
- Sponsor
- Sanofi
- Start
- May 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of amlitelimab in atopic dermatitis (AD), sponsored by Sanofi. Primary endpoint: Treatment-emergent adverse events. Started May 2022; status: active.
02
Drugs
amlitelimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2021-002344-73.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002344-73.